OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer

February 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Dr. Finn on Results of RESOURCE Study in Liver Cancer

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

Dr. Klopp on Data Comparing Standard Radiation With IMRT in Gynecologic Malignancies

January 31st 2017

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses data from a trial comparing standard radiation therapy with intensity-modulated radiation therapy in patients with gynecologic malignancies.

Dr. Finn on Studies of Pembrolizumab for Hepatocellular Carcinoma

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer

January 31st 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Dr. Al-Batran on Paclitaxel Plus Everolimus in Gastric Cancer

January 30th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

Dr. Weiss on PD-L1 Biomarker in Lung Cancer

January 30th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.

Dr. Zhang on Challenges With Vaccines in Renal Cell Carcinoma

January 28th 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.

Dr. Lin on Advances in Radiation Therapy for Esophageal Cancer

January 28th 2017

Steven H. Lin, MD, PhD, associate professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses advances in radiation therapy for patients with esophageal cancer.

Dr. Sears on Microbiota in Colon Cancer

January 28th 2017

Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.

Dr. Sklar on Immunotherapy Potential in Bladder Cancer

January 28th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.

Dr. Hope on Benefits of Gallium 68-Dotatate PET Scan

January 27th 2017

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the Gallium 68-Dotatate PET scan in the imaging of neuroendocrine tumors (NETs).

Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer

January 27th 2017

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Dr. Motzer on the Milestone of Immunotherapy in RCC

January 27th 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Dr. Talamonti on Challenges Facing Minimally Invasive Surgery for Pancreatic Cancer

January 27th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the challenges facing minimally invasive surgery for patients with pancreatic cancer.

Dr. O'Reilly on Tarextumab Combinations for Metastatic Pancreatic Cancer

January 27th 2017

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses tarextumab combinations for patients with pancreatic cancer.

Dr. Kantoff on Docetaxel Plus Androgen Deprivation Therapy in Prostate Cancer

January 26th 2017

Philip W. Kantoff, MD, chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the combination of docetaxel (Taxotere) chemotherapy and androgen deprivation therapy (ADT) in the setting of metastatic hormone-sensitive prostate cancer.

Dr. Rathkopf on AR-V7 Biomarker in Prostate Cancer

January 26th 2017

Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

Dr. Chiorean on Combination Therapies for Pancreatic Cancer

January 26th 2017

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.